← 홈

CGT · 다발성 골수종

131개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 131개
CGTBiologicThe First Affiliated Hospital o…Preclinical

Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis. (Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis.)

Autoimmune Diseases · CD19

#CD19#CGT#Preclinical#세포유전치료#CAR-T+3
임상시험 3상태 RECRUITING
CGTBiologicJuno Therapeutics, Inc., a Bris…Phase 2

Arlocabtagene Autoleucel (Arlocabtagene Autoleucel)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 3상태 RECRUITING
CGTBiologicstaleCARsgen Therapeutics Co., Ltd.Phase 2

CAR-BCMA T Cells (CAR-BCMA T Cells)

Refractory or Relapsed Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 3상태 ACTIVE
CGTBiologicstaleBeijing BiotechPhase 1

CD20/BCMA-directed CAR-T cells (CD20/BCMA-directed CAR-T cells)

Systemic Lupus Erythematosus (SLE); Immune-mediated Necrotizing Myopathy (IMNM) · CD20

#CD20#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 3상태 RECRUITING
CGTBiologicstaleAnhui Provincial HospitalPreclinical

Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis. (Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis.)

Immune Thrombocytopenia (ITP) · CD19

#CD19#CGT#Preclinical#세포유전치료#CAR-T+3
임상시험 2상태 RECRUITING
CGTBiologicstaleYake Biotechnology Ltd.Phase 1

Assigned Interventions CD19/BCMA CAR T-cells (Assigned Interventions CD19/BCMA CAR T-cells)

Scleroderma; Autoimmune Diseases · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 2상태 ACTIVE
CGTBiologicstaleYake Biotechnology Ltd.Phase 2

BCMA CAR-T cells (BCMA CAR-T cells)

Multiple Myeloma; New Diagnosis Tumor · BCMA

#BCMA#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 2상태 ACTIVE
CGTBiologicstaleBioray LaboratoriesPhase 2

BCMA-CART (BCMA-CART)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 2상태 DISCONTINUED
CGTBiologicstaleEssen BiotechPhase 2

CD19/BCMA CAR T-cells (CD19/BCMA CAR T-cells)

Systemic Lupus Erythematosus; Lupus Nephritis · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 2상태 RECRUITING
CGTBiologicstaleCartesian TherapeuticsPhase 2

Descartes-08 (Descartes-08)

Multiple Myeloma · Antisynthetase Syndrome

#AntisynthetaseSyndrome#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 2상태 RECRUITING
CGTBiologicstaleJuno Therapeutics, a Subsidiary…Phase 2

JCARH125 (JCARH125)

Non Hodgkin Lymphoma; Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase2#세포유전치료#CAR-T+3
효능 ORR 42.9%임상시험 2상태 ACTIVE
CGTBiologicstaleOriCell Therapeutics Co., Ltd.Phase 2

OriCAR-017 (OriCAR-017)

Relapsed and/or Refractory Multiple Myeloma · Neoplasms, Plasma Cell

#NeoplasmsPlasmaCell#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 2상태 RECRUITING
CGTBiologicstaleAutolus LimitedPhase 2

AUTO CAR T cell therapy (AUTO CAR T cell therapy)

Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy; Multiple Myeloma · Patients Followed for up to 15 Years Fol

#PatientsFollowedforupto15YearsFo#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTBiologicM.D. Anderson Cancer Centervedotin (BV) and, in Hodgki…Phase 2

Allogeneic Anti-NY-ESO-1-TCR-IL-15-transduced Cord Blood-derived Natural Killer Cells (Allogeneic Anti-NY-ESO-1-TCR-IL-15-transduced Cord Blood-derived Natural Killer Cells)

Relapsed/Refractory Myeloma · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 1상태 RECRUITING
CGTBiologicstaleNational Cancer Institute (NCI)Phase 1

Anti-B-cell maturation antigen (BCMA, Anti-B-cell maturation antigen, Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells)

Myeloma, Plasma-Cell; Myeloma-Multiple · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 1상태 ACTIVE
CGTBiologicstale920th Hospital of Joint Logisti…Phase 2

Anti-GPRC5D CAR-T cells infusion (Anti-GPRC5D CAR-T cells infusion)

Multiple Myeloma in Relapse; Multiple Myeloma, Refractory · GPRC5D

#GPRC5D#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 1상태 ACTIVE
CGTBiologicstaleBristol-Myers SquibbPhase 1

Anti-Signaling lymphocytic activation molecule F7 (SLAMF7, Anti-Signaling lymphocytic activation molecule F7, Anti-Signaling lymphocytic activation molecule F7 (SLAMF7) chimeric antigen receptor (CAR) T cells)

Myeloma-Multiple; Myeloma, Plasma-Cell · Myeloma-Multiple

#Myeloma-Multiple#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
CGTBiologicstaleFred Hutchinson Cancer CenterPhase 1

Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143 (Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143)

Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+4
효능 ORR 7%임상시험 1상태 ACTIVE
CGTBiologicstaleThe First Affiliated Hospital o…Phase 1

Autologous BCMA CAR-T cells and CD19 CAR-T cells (Autologous BCMA CAR-T cells and CD19 CAR-T cells)

Relapsed or Refractory Multiple Myeloma · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTBiologicstaleHebei Senlang Biotechnology Inc…Phase 2

Autologous BCMA-targeting CAR T cells (Autologous BCMA-targeting CAR T cells)

Multiple Myeloma in Relapse; Multiple Myeloma Refractory · BCMA

#BCMA#CGT#Phase2#세포유전치료#CAR-T+4
효능 ORR 96.6%임상시험 1상태 RECRUITING

2 / 7 페이지

← 이전다음 →